All In Biotech

Drug Trial Radar · NCT01332149

Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy

An 11-week Randomized, Double-blind, Multi Center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (300 Mg/Day) Using A Fixed Dosing Schedule In The Treatment Of Subjects S With Pain Associated With Diabetic Peripheral Neuropathy.

Last checked: Nov 20, 2026Latest source record: Jan 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 626 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

626

Actual

Start

Jul 2011

Primary completion

Apr 2014

Study completion Jun 2014

Sponsor

Sponsor type
Industry
First posted
Apr 8, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pregabalin has proven effective in previous clinical trails in other countries in relieving neuropathic pain associated with postherpetic neuralgia and painful diabetic neuropathy. This study is being conducted according to China registration requirement to submit a reapplication with new local diabetic peripheral neuropathy study as a commitment plus the existing data to apply for Lyrica "pain associated with postherpetic neuralgia" indication after Lyrica "pain associated with postherpetic neuralgia" is approved.

Conditions

  • Diabetic Neuropathy, Painful

Interventions

  • PregabalinDrug

    Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn. At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day.

  • Placebo matched with pregabalinDrug

    Subject will take placebo matched with pregabalin twice a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Baseline Mean Pain ScoreTime frame: Baseline
  2. Change From Baseline in Mean Pain Score at EndpointTime frame: Baseline and end of fixed dose phase (Day 63/Week 9)/Early Termination (Study Endpoint)

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital affiliated to Capital Medical University, Neurology Department

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Endocrinology Department

    Beijing, China

  • Beijing Hospital of the Ministry of Health

    Beijing, China

  • Tongren Hospital Affiliated to Capital Medical University

    Beijing, China

  • Chinese PLA General Hospital

    Beijing, China

  • GuangZhou First Municipal People's Hospital

    Guangzhou, China

  • Shanghai Changzheng Hospital

    Shanghai, China

  • Huashan Hospital Affiliated Fudan University, Neurology Department

    Shanghai, China

  • Shanghai Tenth People's Hospital/The Endocrinology Department

    Shanghai, China

  • Shanghai First People's Hospital

    Shanghai, China

  • Renji Hospital Shanghai Jiao Tong University School of Medicine/Neurology Department

    Shanghai, China

  • Southwest hospital of the third military medical university/Department of Neurology

    Chongqing, Chongqing Municipality, China

  • Fuzhou General Hospital of Nanjing Military Command

    Fuzhou, Fujian, China

  • Department of Endocrinology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China

  • Dept. of Endocrinology, The first Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Dept. of Endocrinology, The second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Tongji Hospital,Tongji Medical College Huazhong University of Science & Technology

    Wuhan, Hubei, China

  • Xiangya Hospital of Centre-south University

    Changsha, Hunan, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Dept. of Endocrinology, The second hospital of Jilin University

    Changchun, Jilin, China

  • Shengjing hospital of china medical university

    Shenyang, Liaoning, China

  • Qilu Hospital of Shandong University/department of internal neurology

    Jinan, Shandong, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

  • The Second Affiliated Hospital Zhejiang University College of Medicine

    Hangzhou, Zhejiang, China

  • Sir Run Run Shaw Hospital, School of medicine, Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.